You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKinsey
Baxter
Merck
Boehringer Ingelheim

Last Updated: July 8, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REVLIMID

» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Revlimid

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00974233 Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed Celgene Corporation Phase 2 2009-10-01 The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Combination NCT00974233 Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed University of Wisconsin, Madison Phase 2 2009-10-01 The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Revlimid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00056160 CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed Celgene Corporation Phase 3 2003-01-01 Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
NCT00067743 A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) Completed Celgene Corporation Phase 2 2003-08-01 This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally. For each subject the study consists of two phases: Pre-treatment phase(1 wk) and treatment phase (12 wks)
NCT00087672 A Phase II Study of CC-5013 in Myelofibrosis Completed Celgene Corporation Phase 2 2004-07-01 The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.
NCT00087672 A Phase II Study of CC-5013 in Myelofibrosis Completed M.D. Anderson Cancer Center Phase 2 2004-07-01 The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.
NCT00093028 Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II Completed University of Arkansas Phase 3 2004-01-01 The purpose of this study is - to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™), - to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment, - to learn if a patient's genetic makeup before and after treatment can predict which patients will respond to bortezomib and Revlimid™, and to learn more about how the body responds (gene array studies).
NCT00098475 Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma Active, not recruiting National Cancer Institute (NCI) Phase 3 2004-10-01 This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide and thalidomide may also stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide, thalidomide, and dexamethasone together may kill more cancer cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Revlimid

Condition Name

Condition Name for Revlimid
Intervention Trials
Multiple Myeloma 110
Chronic Lymphocytic Leukemia 32
Lymphoma 22
Leukemia 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Revlimid
Intervention Trials
Multiple Myeloma 187
Neoplasms, Plasma Cell 183
Lymphoma 108
Leukemia 79
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Revlimid

Trials by Country

Trials by Country for Revlimid
Location Trials
Canada 123
Spain 50
Germany 48
France 48
Italy 46
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Revlimid
Location Trials
Texas 96
New York 87
California 85
Ohio 73
Florida 68
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Revlimid

Clinical Trial Phase

Clinical Trial Phase for Revlimid
Clinical Trial Phase Trials
Phase 4 3
Phase 3 52
Phase 2/Phase 3 3
[disabled in preview] 392
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Revlimid
Clinical Trial Phase Trials
Completed 120
Active, not recruiting 106
Recruiting 97
[disabled in preview] 131
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Revlimid

Sponsor Name

Sponsor Name for Revlimid
Sponsor Trials
Celgene Corporation 173
National Cancer Institute (NCI) 94
M.D. Anderson Cancer Center 51
[disabled in preview] 77
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Revlimid
Sponsor Trials
Other 412
Industry 358
NIH 97
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
AstraZeneca
Dow
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.